Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy in Rectal Cancer Patients

Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy in Rectal Cancer Patients is a phase 3, randomised interventional study registered as NCT04095299 by Vejle Hospital, with a registry enrolment figure of 162 participants, started 2020-01-20 and due to reach its primary completion in 2026-12. Interventions recorded: 50.4 Gy to the tumor and elective volume; 62 Gy to the clinical tumor volume and 50.4 Gy to the elective volume; Capecitabine 825 mg/m2 twice daily on weekdays. Conditions listed: Cancer of Rectum. Primary outcome: Rectal preservation at two years. Colorectal eligibility wording from the registry: "* Histopathologically verified adenocarcinoma of the rectum". Sites: Denmark. No results are recorded here; the registry entry is the source.